Business Wire

LARSEN-&-TOUBRO-INFOTECH

6.2.2020 12:02:04 CET | Business Wire | Pressemeddelelse

Del
LTI Udvider Strategisk Partnerskab med OKQ8 Scandinavia

Larsen & Toubro Infotech Ltd. (NSE: LTI, BSE: 540005), er en global virksomhed inden for teknologirådgivning og digitale løsninger, har udvidet sin aftale med OKQ8 AB Scandinavia. I løbet af de næste fem år vil denne aftale tranformere applikationer og OKQ8’s infrastruktur landskab med tjenester der omfatter Infrastruktur-as-a-Service (IaaS), Sikkerhedstjenester, Applikationsdrift, Vedligeholdelse og Udvikling, hvilket vil resultere i forbedret stabilitet, tilgængelighed og forudsigelighed af it-driften.

OKQ8, der har hovedkvarter i Stockholm, er en af Skandinaviens største brændstofvirksomheder med en omsætning på over 39 mia. SEK og tæt på 1000 stationer over hele Danmark og Sverige. LTI har været partner med OKQ8 siden 2017, og denne udvidede aftaler er et resultat af, hvad dette partnerskab har skabt gennem årene. Som en strategisk partner vil LTI udnytte sine omfattende evner indenfor analyse, automatisering og KI til at levere disse servicer til OKQ8.

Mikael Pålsson, CIO, OKQ8 , udtaler, “For at kunne betjene vores kunder bedre er det afgørende for OKQ8 at integrere vores økosystem som består af brændstofstationer, dagligvarebutikker, bilvaske, biludlejninger samt økonomi- og forsikringsservicer. Som vores strategiske partner bringer LTI den rette erfaring, teknologiske kompetence og kulturelle tilpasning der sikrer, at dette program bliver en fuldkommen succes.”

Arun Sankaranarayanan, Chief Business Officer, LTI Nordics , udtaler, “Siden begyndelsen I 1999 har OKQ8 konsekvent sat høje standarder for teknologiudnyttelse og ekspertise indenfor kundeservice. Vi er glade for at udvide vores partnerskab med OKQ8 for at designe næste generations arkitektur og opfylde virksomhedens vision for digital transformation. LTI vil udnytte sine evner indenfor eksponentielle teknologier og kundecentrisk tilgang til at hjælpe OKQ8 med at nå sine strategiske mål.”

LTI har en stærk tilstedeværelse I hele Norden og samarbejder med førende virksomheder for at hjælpe dem med at konkurrere effektivt i en verden i forandring.

Om LTI:

LTI (NSE: LTI) er en global virksomhed inden for teknologirådgivning og digitale løsninger, der hjælper over 420 klienter med at få succes i en konvergerende verden. Med operationer I 32 lande går vi den ekstra mil for vores klienter og fremskynder deres digitale transformation med LTIs Mosaic platform, som muliggør deres mobile, sociale, analytiske, IoT og cloud-baserede rejser. Vi blev grundlagt I 1997 som et datterselskab af Larsen & Toubro Limited, og vores unikke arv giver os en uovertruffen ekspertise til at løse de mest komplekse udfordringer for virksomheder på tværs af alle brancher. Hver dag giver vores team, på over 30.000 LTI-medarbejdere, vores kunder mulighed for at forbedre effektiviteten af deres forretnings- og teknologidrift samt levere værdi til deres kunder, medarbejdere og aktionærer. Læs mere på http://www.Lntinfotech.com eller følg os på @LTI_Global

Om OKQ8 AB :

OKQ8 Scandinavia: Den foretrukne mulighed for bæredygtig bevægelse

OKQ8 Scandinavia har operationer I Sverige og Danmark og er en af Skandinaviens største brændstofvirksomheder. Vi er en organisation med omkring 5000 ansatte som er engagerede, kundeorienterede og har fokus på bæredygtighed. Vi arbejder aktivt på at drive udviklingen af mere klima- og miljøvenlige brændstoffer og produkter fremad, på at reducere ulighed og på at bidrage til bæredygtige byer og samfund. Med omkring 1000 servicestationer, vores egen bank og et af markedets stærkeste virksomhedstilbud ønsker vi at være den foretrukne mulighed for bæredygtig forretning – både nu og i fremtiden. Læs mere på www.okq8.se

Forbind til LTI:

Link:

ClickThru

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye